ArticleThe Journal of physiology2025
Heart dysfunction in a rat model with autosomal recessive polycystic kidney disease.
Article in The Journal of physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Autosomal recessive polycystic kidney disease (ARPKD) is a congenital hepatorenal fibrocystic pathology and is one of the most significant childhood nephropathies leading to chronic kidney disease (CKD). While kidney damage has been well studied in this pathology, only a few studies have investigated specific cardiac damage during ARPKD. This study aimed to conduct a large analysis of heart dysfunction during the progression of CKD. ARPKD rats with the Pkhd1 gene mutation (IVS35-2A>T) were monitored for CKD progression and heart dysfunction via echocardiography. Heart fibrosis was assessed using Sirius red staining, and cardiokines mRNA expressions in heart tissue were analysed. ARPKD rats exhibited increased blood pressure, cardiac hypertrophy and thickening of the left ventricular posterior wall, correlated with elevated plasma creatinine levels. Diastolic dysfunction was evident, shown by altered E/A and E/e' ratios, which worsened with CKD severity. Heart fibrosis correlated with renal dysfunction, and fibrosis signalling pathways were activated, marked by increased galectin-3, collagen-1, fibroblast growth factor 23, suppressor of tumorigenicity 2 (ST2) and soluble ST2 expression. Growth differentiation factor 15 levels rose with CKD progression, while Irisin levels decreased, negatively correlating with the E/e' ratio. This study highlights diastolic dysfunction, heart fibrosis, and hypertrophy in ARPKD rats with severe CKD. These cardiac changes are linked to dysregulation in cardiokine signalling, providing new insights into uraemia-induced heart failure in ARPKD KEY POINTS: Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic disorder with a reduced life expectancy and a broad clinical spectrum including systemic hypertension, renal failure, portal hypertension, and renal and hepatic fibrosis. PCK rats have a spontaneous mutation in the Pkhd1 gene, the same gene affected in human ARPKD. PCK rats develop renal and hepatic cysts and other manifestations of human ARPKD. Changes in heart tissue (fibrosis, hypertrophy) and diastolic dysfunction (decreasing E/A and increasing E/e' ratios) worsen with renal dysfunction in PCK rats. Heart dysfunctions are associated with a dysregulation of cardiokine signalling such as Irisin, in PCK rats. Irisin could be a new marker of diastolic function in ARPKD and chronic kidney disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.